BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10782561)

  • 1. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
    Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
    Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
    Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
    Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
    Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
    Testa R; Bonfigli AR; Pieri C; Marra M; Sirolla C; Manfrini S; Testa I
    Int J Clin Lab Res; 1998; 28(3):187-91. PubMed ID: 9801931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
    Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
    Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
    Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
    Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) in South Indian type 2 diabetic subjects in relation to diabetic vascular complications.
    Deepa R; Mohan A; Rema M; Haranath SP; Saravanan G; Mohan V
    J Assoc Physicians India; 2002 May; 50(5):657-61. PubMed ID: 12186119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
    Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
    Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.
    Jae SY; Heffernan KS; Lee MK; Fernhall B; Park WH
    Am J Cardiol; 2008 Sep; 102(6):700-3. PubMed ID: 18773991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
    Testa R; Bonfigli AR; Piantanelli L; Manfrini S; Testa I; Gregorio F
    Diabetes Res Clin Pract; 1996 Jul; 33(2):111-8. PubMed ID: 8879966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.
    Vignini A; Nanetti L; Moroni C; Testa R; Sirolla C; Marra M; Manfrini S; Fumelli D; Marcheselli F; Mazzanti L; Rabini RA
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):15-22. PubMed ID: 17949955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: relationship to metabolic parameters and diabetic complications.
    Tarkun I; Cetinarslan B; Cantürk Z
    Nutr Metab Cardiovasc Dis; 2002 Jun; 12(3):127-31. PubMed ID: 12325469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
    Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM; Barrow BA; Grant PJ; Levy JC
    Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between lipoprotein(a) and the complications of diabetes mellitus.
    Koschinsky ML; Marcovina SM
    Acta Diabetol; 2003 Jun; 40(2):65-76. PubMed ID: 12861403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes.
    Sahli D; Eriksson JW; Boman K; Svensson MK
    Thromb Res; 2009 Mar; 123(5):701-6. PubMed ID: 18945481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients.
    Hernández C; Chacón P; García-Pascual L; Mesa J; Simó R
    Thromb Res; 2000 Jul; 99(2):119-27. PubMed ID: 10946085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.